Thromboprophylaxis in surgical and medical patients

Seminars in Respiratory and Critical Care Medicine

Volumn 33, Issue 2, 2012, Pages 163-175

  Bozzato, Silvia ^a   Galli, Luca ^a   Ageno, Walter ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

anticoagulation; deep venous thrombosis; fondaparinux; heparin; thromboprophylaxis; warfarin

Indexed keywords

AMIODARONE; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; BETRIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN; DABIGATRAN ETEXILATE; DALTEPARIN; DAREXABAN; DEXAMETHASONE; EDOXABAN; ENOXAPARIN; FONDAPARINUX; HEPARIN; LETAXABAN; LOW MOLECULAR WEIGHT HEPARIN; N [2 [4 (1 METHYL 4 PIPERIDINYL) 1 PIPERAZINYL] 2 OXO 1 PHENYLETHYL] 1H INDOLE 6 CARBOXAMIDE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; QUINIDINE; RECOMBINANT ERYTHROPOIETIN; RIVAROXABAN; TAMOXIFEN; THALIDOMIDE; THROMBIN INHIBITOR; WARFARIN;

ANEMIA; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BLEEDING; BREAST CANCER; CANCER PATIENT; CARDIOVASCULAR EQUIPMENT; CLINICAL EDUCATION; CLINICAL PRACTICE; CLINICAL PROTOCOL; COMPRESSION GARMENT; CONTROLLED DRUG RELEASE; DEEP VEIN THROMBOSIS; DRUG DOSE REGIMEN; DRUG EFFICACY; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH RISK PATIENT; HOSPITAL PATIENT; HUMAN; INTERMITTENT PNEUMATIC COMPRESSION DEVICE; LOW DRUG DOSE; LUNG EMBOLISM; MOBILIZATION; MULTIPLE MYELOMA; ORTHOPEDIC SURGERY; PHARMACODYNAMICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SURGICAL PATIENT; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; COMBINED MODALITY THERAPY; EVIDENCE-BASED MEDICINE; HOSPITALIZATION; HUMANS; INTERMITTENT PNEUMATIC COMPRESSION DEVICES; POSTOPERATIVE COMPLICATIONS; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; STOCKINGS, COMPRESSION; SURGICAL PROCEDURES, OPERATIVE; VENOUS THROMBOEMBOLISM;

EID: 84861633367     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0032-1311795     Document Type: Article

References (93)

1. Anderson FA Jr, Wheeler HB, Goldberg RJ., et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med: 1991; 151 5 933 938
2. Geerts WH, Pineo GF, Heit JA., et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest: 2004; 126 3 Suppl 338S 400S (Pubitemid 39302602)
3. Lindblad B, Sternby NH, Bergqvist D. Incidence of venous thromboembolism verified by necroscopy over 30 years. BMJ: 1991; 302 6778 709 711
4. Sandler DA, Martin JF. Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis? J R Soc Med: 1989; 82 4 203 205 (Pubitemid 19086881)
5. Alikhan R, Peters F, Wilmott R, Cohen AT. Fatal pulmonary embolism in hospitalised patients: a necropsy review. J Clin Pathol: 2004; 57 12 1254 1257 (Pubitemid 39611508)
6. Otero R, Uresandi F, Cayuela A., et al. Use of venous thromboembolism prophylaxis for surgical patients: a multicentre analysis of practice in Spain. Eur J Surg: 2001; 167 3 163 167 (Pubitemid 32231951)
7. Yu HT, Dylan ML, Lin J, Dubois RW. Hospitals' compliance with prophylaxis guidelines for venous thromboembolism. Am J Health Syst Pharm: 2007; 64 1 69 76 (Pubitemid 46395711)
8. Cohen AT, Tapson VF, Bergmann JF., et al. ENDORSE Investigators Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet: 2008; 371 9610 387 394 (Pubitemid 351173321)
9. Stratton MA, Anderson FA, Bussey HI., et al. Prevention of venous thromboembolism: adherence to the 1995 American College of Chest Physicians consensus guidelines for surgical patients. Arch Intern Med: 2000; 160 3 334 340 (Pubitemid 30075215)
10. Tapson VF, Decousus H, Pini M., et al. IMPROVE Investigators Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism. Chest: 2007; 132 3 936 945
11. Kahn SR, Panju A, Geerts W., et al. CURVE study investigators Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada. Thromb Res: 2007; 119 2 145 155 (Pubitemid 44810862)
12. Cohen AT, Agnelli G, Anderson FA., et al. VTE Impact Assessment Group in Europe (VITAE) Venous thromboembolism (VTE) in Europe: the number of VTE events and associated morbidity and mortality. Thromb Haemost: 2007; 98 4 756 764 (Pubitemid 47555066)
13. Ageno W, Dentali F. Prevention of in-hospital VTE: why can't we do better? Lancet: 2008; 371 9610 361 362 (Pubitemid 351173303)
14. Samama MM, Cohen AT, Darmon JY., et al. Prophylaxis in Medical Patients with Enoxaparin Study Group A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med: 1999; 341 11 793 800 (Pubitemid 29420474)
15. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ.; PREVENT Medical Thromboprophylaxis Study Group Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation: 2004; 110 7 874 879 (Pubitemid 39096017)
16. Geerts WH, Bergqvist D, Pineo GF., et al. American College of Chest Physicians Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest: 2008; 133 6, Suppl 381S 453S (Pubitemid 351894916)
17. Gangireddy C, Rectenwald JR, Upchurch GR., et al. Risk factors and clinical impact of postoperative symptomatic venous thromboembolism. J Vasc Surg: 2007; 45 2 335 341, discussion 341-342
18. Turpie AG, Bauer KA, Caprini JA, Comp PC, Gent M, Muntz JE.; Apollo Investigators Fondaparinux combined with intermittent pneumatic compression vs. intermittent pneumatic compression alone for prevention of venous thromboembolism after abdominal surgery: a randomized, double-blind comparison. J Thromb Haemost: 2007; 5 9 1854 1861 (Pubitemid 47288942)
19. Agnelli G, Bolis G, Capussotti L., et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg: 2006; 243 1 89 95 (Pubitemid 43054059)
20. Hendolin H, Mattila MA, Poikolainen E. The effect of lumbar epidural analgesia on the development of deep vein thrombosis of the legs after open prostatectomy. Acta Chir Scand: 1981; 147 6 425 429 (Pubitemid 12233563)
21. International Multicenter Trial Prevention of fatal postoperative pulmonary embolism by low doses of heparin. An international multicentre trial. Lancet: 1975; 2 7924 45 51
22. Clagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients: results of meta-analysis. Ann Surg: 1988; 208 2 227 240
23. Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin: overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med: 1988; 318 18 1162 1173
24. Mismetti P, Laporte S, Darmon JY, Buchmüller A, Decousus H. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg: 2001; 88 7 913 930 (Pubitemid 34015572)
25. Agnelli G, Bergqvist D, Cohen AT, Gallus AS, Gent M.; PEGASUS investigators Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg: 2005; 92 10 1212 1220 (Pubitemid 41475229)
26. Gallus AS. Prevention of post-operative deep leg vein thrombosis in patients with cancer. Thromb Haemost: 1997; 78 1 126 132 (Pubitemid 27289229)
27. Kakkar AK, Williamson RC. Prevention of venous thromboembolism in cancer patients. Semin Thromb Hemost: 1999; 25 2 239 243 (Pubitemid 29227152)
28. Bergqvist D. Venous thromboembolism and cancer: prevention of VTE. Thromb Res: 2001; 102 6 V209 V213 (Pubitemid 32539211)
29. Kakkar AK, Haas S, Wolf H, Encke A. Evaluation of perioperative fatal pulmonary embolism and death in cancer surgical patients: the MC-4 cancer substudy. Thromb Haemost: 2005; 94 4 867 871 (Pubitemid 41489251)
30. Agnelli G, Bolis G, Capussotti L., et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg: 2006; 243 1 89 95 (Pubitemid 43054059)
31. Bergqvist D, Agnelli G, Cohen AT., et al. ENOXACAN II Investigators Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med: 2002; 346 13 975 980 (Pubitemid 34983247)
32. Rasmussen MS, Jorgensen LN, Wille-Jorgensen P., et al. FAME Investigators Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. J Thromb Haemost: 2006; 4 11 2384 2390 (Pubitemid 44575433)
33. Kearon C. Natural history of venous thromboembolism. Circulation: 2003; 107 23, Suppl 1 I22 I30 (Pubitemid 41289268)
34. Mismetti P, Laporte S, Zufferey P, Epinat M, Decousus H, Cucherat M. Prevention of venous thromboembolism in orthopedic surgery with vitamin K antagonists: a meta-analysis. J Thromb Haemost: 2004; 2 7 1058 1070 (Pubitemid 40186077)
35. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med: 2002; 162 16 1833 1840
36. Hull RD, Pineo GF, Stein PD., et al. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann Intern Med: 2001; 135 10 858 869 (Pubitemid 33070682)
37. Eriksson BI, Lassen MR.; PENTasaccharide in HIp-FRActure Surgery Plus Investigators Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. Arch Intern Med: 2003; 163 11 1337 1342 (Pubitemid 36676199)
38. Ettema HB, Hoppener MR, Veeger NJ, Büller HR, van der Meer J. Low incidence of venographically detected deep vein thrombosis after knee arthroscopy without thromboprophylaxis: a prospective cohort study. J Thromb Haemost: 2006; 4 6 1411 1413
39. Hoppener MR, Ettema HB, Henny CP, Verheyen CC, Büller HR. Low incidence of deep vein thrombosis after knee arthroscopy without thromboprophylaxis: a prospective cohort study of 335 patients. Acta Orthop: 2006; 77 5 767 771 (Pubitemid 44521917)
40. Wirth T, Schneider B, Misselwitz F., et al. Prevention of venous thromboembolism after knee arthroscopy with low-molecular weight heparin (reviparin): results of a randomized controlled trial. Arthroscopy: 2001; 17 4 393 399
41. Michot M, Conen D, Holtz D., et al. Prevention of deep-vein thrombosis in ambulatory arthroscopic knee surgery: a randomized trial of prophylaxis with low-molecular-weight heparin. Arthroscopy: 2002; 18 3 257 263 (Pubitemid 36114580)
42. Camporese G, Bernardi E, Prandoni P., et al. KANT (Knee Arthroscopy Nadroparin Thromboprophylaxis) Study Group Low-molecular-weight heparin versus compression stockings for thromboprophylaxis after knee arthroscopy: a randomized trial. Ann Intern Med: 2008; 149 2 73 82 (Pubitemid 352008595)
43. Geerts WH, Heit JA, Clagett GP., et al. Prevention of venous thromboembolism. Chest: 2001; 119 1, Suppl 132S 175S (Pubitemid 32162075)
44. Collen JF, Jackson JL, Shorr AF, Moores LK. Prevention of venous thromboembolism in neurosurgery: a metaanalysis. Chest: 2008; 134 2 237 249
45. Turner JA, Ersek M, Herron L., et al. Patient outcomes after lumbar spinal fusions. JAMA: 1992; 268 7 907 911
46. Oda T, Fuji T, Kato Y, Fujita S, Kanemitsu N. Deep venous thrombosis after posterior spinal surgery. Spine: 2000; 25 22 2962 2967
47. Goldhaber SZ, Tapson VF.; DVT FREE Steering Committee A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. Am J Cardiol: 2004; 93 2 259 262 (Pubitemid 38058748)
48. Sandler DA, Martin JF. Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis? J R Soc Med: 1989; 82 4 203 205 (Pubitemid 19086881)
49. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ III. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med: 2000; 160 6 809 815 (Pubitemid 30165241)
50. Vaitkus PT, Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Goldhaber SZ.; PREVENT Medical Thromboprophylaxis Study Group Mortality rates and risk factors for asymptomatic deep vein thrombosis in medical patients. Thromb Haemost: 2005; 93 1 76 79 (Pubitemid 40124258)
51. Alikhan R, Cohen AT, Combe S., et al. MEDENOX Study Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Arch Intern Med: 2004; 164 9 963 968 (Pubitemid 38581515)
52. Dentali F, Douketis JD, Gianni M, Lim W, Crowther MA. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Intern Med: 2007; 146 4 278 288 (Pubitemid 351650614)
53. Kanaan AO, Silva MA, Donovan JL, Roy T, Al-Homsi AS. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients. Clin Ther: 2007; 29 11 2395 2405
54. Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood: 2005; 106 8 2710 2715 (Pubitemid 41510744)
55. Cohen AT, Davidson BL, Gallus AS., et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ: 2006; 332 7537 325 329
56. Hull RD, Schellong SM, Tapson VF., et al. EXCLAIM (Extended Prophylaxis for Venous ThromboEmbolism in Acutely Ill Medical Patients With Prolonged Immobilization) study Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med: 2010; 153 1 8 18
57. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA: 2005; 293 6 715 722 (Pubitemid 40216041)
58. Arkel YS. Thrombosis and cancer. Semin Oncol: 2000; 27 3 362 374 (Pubitemid 30395168)
59. Elting LS, Escalante CP, Cooksley C., et al. Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med: 2004; 164 15 1653 1661 (Pubitemid 39037944)
60. Blom JW, Vanderschoot JP, Oostindiër MJ, Osanto S, van der Meer FJ, Rosendaal FR. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost: 2006; 4 3 529 535
61. Prandoni P, Lensing AW, Piccioli A., et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood: 2002; 100 10 3484 3488 (Pubitemid 35303914)
62. Descourt R, Le Gal G, Couturaud F., et al. Recurrent venous thromboembolism under anticoagulant therapy: a high risk in adenocarcinoma? Thromb Haemost: 2006; 95 5 912 913
63. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med: 2000; 343 25 1846 1850 (Pubitemid 32104130)
64. Alcalay A, Wun T, Khatri V., et al. Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival. J Clin Oncol: 2006; 24 7 1112 1118 (Pubitemid 46638808)
65. Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med: 2006; 166 4 458 464
66. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer: 2007; 110 10 2339 2346 (Pubitemid 350100757)
67. Lyman GH, Khorana AA, Falanga A., et al. American Society of Clinical Oncology American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol: 2007; 25 34 5490 5505 (Pubitemid 350232226)
68. Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation: 2003; 107 23, Suppl 1 I17 I21 (Pubitemid 41289267)
69. Fisher B, Costantino JP, Wickerham DL., et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst: 2005; 97 22 1652 1662 (Pubitemid 41672231)
70. Bohlius J, Wilson J, Seidenfeld J., et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst: 2006; 98 10 708 714 (Pubitemid 43821788)
71. Khorana AA, Francis CW, Blumberg N, Culakova E, Refaai MA, Lyman GH. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med: 2008; 168 21 2377 2381
72. Bern MM, Lokich JJ, Wallach SR., et al. Very low doses of warfarin can prevent thrombosis in central venous catheters: a randomized prospective trial. Ann Intern Med: 1990; 112 6 423 428 (Pubitemid 20098523)
73. Randolph AG, Cook DJ, Gonzales CA, Andrew M. Benefit of heparin in central venous and pulmonary artery catheters: a meta-analysis of randomized controlled trials. Chest: 1998; 113 1 165 171 (Pubitemid 28044941)
74. Akl EA, van Doormaal FF, Barba M., et al. Parenteral anticoagulation for prolonging survival in patients with cancer who have no other indication for anticoagulation. Cochrane Database Syst Rev: 2007; 3 CD006652
75. Weitz JI, Hirsh J, Samama MM.; American College of Chest Physicians New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest: 2008; 133 6, Suppl 234S 256S (Pubitemid 351892968)
76. Eriksson BI, Borris LC, Friedman RJ., et al. RECORD1 Study Group Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med: 2008; 358 26 2765 2775 (Pubitemid 351930851)
77. Kakkar AK, Brenner B, Dahl OE., et al. RECORD2 Investigators Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet: 2008; 372 9632 31 39
78. Lassen MR, Ageno W, Borris LC., et al. RECORD3 Investigators Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med: 2008; 358 26 2776 2786 (Pubitemid 351930852)
79. Turpie AG, Lassen MR, Davidson BL., et al. RECORD4 Investigators Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet: 2009; 373 9676 1673 1680
80. Turpie AG, Lassen MR, Eriksson BI., et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty: pooled analysis of four studies. Thromb Haemost: 2011; 105 3 444 453
81. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med: 2009; 361 6 594 604
82. Lassen MR, Raskob GE, Gallus AS, Pineo G, Chen D, Hornick P.; ADVANCE-2 investigators Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet: 2010; 375 9717 807 815
83. Lassen MR, Gallus A, Raskob GE., et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med: 2010; 363 26 2487 2498
84. Raskob G, Cohen AT, Eriksson BI., et al. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study. Thromb Haemost: 2010; 104 3 642 649
85. Weitz JI, Cao C, Eriksson BI., et al. A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery. Thromb Haemost: 2010; 104 6 1150 1157
86. Turpie AG, Bauer KA, Davidson BL., et al. EXPERT Study Group A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT). Thromb Haemost: 2009; 101 1 68 76
87. Eriksson BI, Turpie AG, Lassen MR., et al. ONYX-2 STUDY GROUP Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty: a dose finding study (ONYX-2). J Thromb Haemost: 2010; 8 4 714 721
88. Agnelli G, Haas S, Ginsberg JS, Krueger KA, Dmitrienko A, Brandt JT. A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement. J Thromb Haemost: 2007; 5 4 746 753 (Pubitemid 46563573)
89. European Medicines Agency (EMEA) European public assessment report: Pradaxa. http://www.emea.europa.eu. Accessed June 2011
90. Eriksson BI, Dahl OE, Rosencher N., et al. RE-NOVATE Study Group Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet: 2007; 370 9591 949 956 (Pubitemid 47393577)
91. Eriksson BI, Dahl OE, Rosencher N., et al. RE-MODEL Study Group Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost: 2007; 5 11 2178 2185 (Pubitemid 47617868)
92. Ginsberg JS, Davidson BL, Comp PC., et al. RE-MOBILIZE Writing Committee Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty: 2009; 24 1 1 9
93. Friedman RJ, Dahl OE, Rosencher N., et al. RE-MOBILIZE, RE-MODEL, RE-NOVATE Steering Committees Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials. Thromb Res: 2010; 126 3 175 182